It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.
To know that specialized, targeted drugs are pharma's current rallying cry, you didn't have to follow the news out of this month's big cancer meeting. But it's the latest example of how drugmakers are using knowledge of cancer's genetic drivers to develop new treatments.
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
After we assembled this year's ranking of pharma's highest-paid CEOs, we took attendance. And as usual, the absences were telling.
A Bureau of Labor Statistics study found that pharma manufacturing in the U.S. increased output per hour just 0.7% annually from 1987 to 2008.
We're going to take a brief break to rest up so we can come back Monday.
We've completed a major overhaul of FiercePharma's website. Drop us a line with any suggestions or comments you may have.
We've completed a major overhaul of FiercePharma's website. Drop us a line with any suggestions or comments you have.
Tech-savvy scientists can help pull the biopharma industry out of the proverbial muck. FierceBiotech IT has selected a list of 10 innovators who are challenging the status quo in their fields.